Rana Tahbaz
AuthID: R-00H-HAF
11
TITLE: A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
AUTHORS: Bex, A; Albiges, L; Staehler, M; Bensalah, K; Giles, RH; Dabestani, S; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Marconi, L; Merseburger, AS; Fernández Pello, S; Tahbaz, R; Abu Ghanem, Y; Volpe, A; Ljungberg, B; Escudier, B; Powles, T;
PUBLISHED: 2018, SOURCE: European Urology, VOLUME: 74, ISSUE: 6
AUTHORS: Bex, A; Albiges, L; Staehler, M; Bensalah, K; Giles, RH; Dabestani, S; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Marconi, L; Merseburger, AS; Fernández Pello, S; Tahbaz, R; Abu Ghanem, Y; Volpe, A; Ljungberg, B; Escudier, B; Powles, T;
PUBLISHED: 2018, SOURCE: European Urology, VOLUME: 74, ISSUE: 6
INDEXED IN: 
Scopus
Scopus